[Adalimumab therapy for Vogt-Koyanagi-Harada syndrome].
M. DíazLlopis,L. Amselem,R. Fj,S. garcia-Delpech,Hernandez-Hernandez Ml
Archivos de la Sociedad Española de Oftalmología
Abstract:Dear Sir: The purpose of this letter is to report on the efficiency and advantages of the new anti-TNF therapy with adalimumab in the VogtKoyanagi Harada (VKH) syndrome, an inflammatory pathology for which the results of the above drug have not yet been described. A 36-year old male requested attention due to acute and intense loss of vision (VA of 1/10 in both eyes). He exhibited multiple bilateral exudative retina detachments, papillitis and anterior vitreous and vitreous tyndall (fig. 1). After initial treatment with endovenous megadoses of methylprednisolone (1 gr daily/4 days) and subsequent maintenance dosage with prednisone and cyclosporine, the inflammation was resolved and the patient recovered full vision in both eyes. In the following months, the patient developed vitiligo and hair loss as well as depigmented eye fundus in «rising sun» fashion. This confirmed the diagnosis of full VKH. In the following year of evolution, the patient suffered frequent and intense relapses of anterior uveitis in both eyes when attempts were made to reduce the prednisone dose below 50 mgr/day even though the cyclosporine dose was maintained and frequent subtenon injections of triamcinolone were associated. Through a compassionate use application a treatment was established with a fortnightly subcutaneous administration of 40 mg adalimumab (Humira). This treatment was maintained over 8 months to this date, while corticoids were progressively withdrawn and cyclosporine use was discontinued. The patient did not suffer any inflammatory relapse, side effects or iatrogeny. The Tumoral Necrosis Factor (TNF) and interleukin 2 (IL2) are the two main cytokines involved in the development of non-infectious human uveitis (1). A variety of monoclonal antibodies have proved their efficacy against uveitis, both in human and experimentally (2,3). Adalimumab is the first drug of the anti-TNF family which exhibits a dual advantage: being 100% apt for humans and subcutaneous administration. The former prevents the possibility of reactions after administration (fever, low blood pressure, etc.) which have been described in up to 5% of cases of administration of other anti-TNF and anti-IL2 drugs used to date, as well as the need of associating methotrexate to avoid the development of antibodies. In turn, subcutaneous administration allow out-patient treatment, in comparison to the most efficient anti-TNF presently in use for uveitis infliximab which requires endovenous infusion, thus discarding hospital dependency for a monthly dose and improving the quality of life of patients and health system costs. Candidates for this treatment must be assessed previously to exclude latent tuberculosis and evaluate prophylactic measures due to the theoretically increased risk of reactivation thereof. In addition, the side effects which have exceptionally been described (4) are: endogenous endophthalmitis, retrobulbar neuritis and bilateral optic neuropathy, motor eye paralysis, cytopenia, lupic syndrome, general skin eruptions, exacerbation of demyelinizing disease, cardiac failure, lymphoma, increase of transaminase or opportunistic infections. A number of drugs have been utilized in the treatment of relapsing VKH syndrome with variable degrees of efficacy: cyclosporine, chlorambucyl, cyclophosphamide, tacrolimus, mycophenolate, azathioprine, methotrexate and even endovenous immunoglobuline (5). After searching PubMed/Medline, this is the first case which describes the extraordinary efficiency of adalimumab against this syndrome, a good option in refractory cases, without having tested previously any other monoclonal antibody for this pathology. LETTER TO THE EDITOR ARCH SOC ESP OFTALMOL 2007; 82: 131-132